Arrowhead Pharmaceuticals Inc (ARWR) CEO Christopher Richard Anzalone Sells 164,834 Shares

Share on StockTwits

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 164,834 shares of the stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $14.45, for a total transaction of $2,381,851.30. Following the completion of the transaction, the chief executive officer now owns 1,868,789 shares of the company’s stock, valued at approximately $27,004,001.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Christopher Richard Anzalone also recently made the following trade(s):

  • On Friday, August 31st, Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $14.45, for a total transaction of $1,445,000.00.

Shares of NASDAQ ARWR opened at $18.15 on Thursday. Arrowhead Pharmaceuticals Inc has a twelve month low of $2.65 and a twelve month high of $17.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.69 and a quick ratio of 8.69. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -30.00 and a beta of 1.91.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.62 million. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. equities research analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.64 EPS for the current year.

A number of hedge funds have recently modified their holdings of the stock. First Allied Advisory Services Inc. lifted its position in Arrowhead Pharmaceuticals by 5.5% in the second quarter. First Allied Advisory Services Inc. now owns 64,350 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 3,350 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Arrowhead Pharmaceuticals by 28.9% in the second quarter. Janney Montgomery Scott LLC now owns 25,200 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 5,650 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $100,000. Great West Life Assurance Co. Can acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $106,000. Finally, United Services Automobile Association increased its stake in shares of Arrowhead Pharmaceuticals by 69.6% in the second quarter. United Services Automobile Association now owns 19,043 shares of the biotechnology company’s stock valued at $259,000 after buying an additional 7,816 shares in the last quarter. 58.96% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently issued reports on the stock. BidaskClub lowered shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Cantor Fitzgerald reiterated a “buy” rating and issued a $18.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday. S&P Equity Research cut their price target on shares of Arrowhead Pharmaceuticals from $13.76 to $11.68 in a report on Monday, June 18th. Piper Jaffray Companies reissued an “overweight” rating and issued a $17.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, June 29th. Finally, Chardan Capital set a $16.00 price target on shares of Arrowhead Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, July 8th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $17.03.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Story: Market Capitalization in the Stock Market

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply